Overview
- Moderna reported on July 31 that second-quarter revenue was $145 million, which beat the $103 million consensus reported by LSEG.
- The company narrowed its quarterly net loss to $782 million and trimmed 2026 cost and research spending forecasts to preserve cash.
- An interim analysis of Moderna’s Phase 3 norovirus vaccine failed to meet the trial’s prespecified statistical benchmark, the study remains blinded and the company plans to enroll an additional patient cohort.
- The U.S. Food and Drug Administration set an August 5 action date for Moderna’s seasonal influenza candidate mRNA-1010 following a prior refusal to accept the application.
- Investors priced the mixed news into the stock with a roughly 4–6% premarket decline and the company’s near-term outlook now hinges on the FDA decision, future late-stage readouts and how quickly cost cuts translate into sustainable cash flow.